A Study of CDX-0159 in Patients With Prurigo Nodularis

Completed · Phase 1 · Has a placebo group

Conditions studied: Prurigo Nodularis

In brief

The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.

Key facts

Study ID
NCT04944862
Run by
Celldex Therapeutics
People needed
24
Starts
2021-11-08
Expected to finish
2023-07-31
Last updated by the study team
2023-08-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.